Study Notes on Acetylcholine and Dopamine in Chronic Neurological Conditions

Introduction to Chronic Neurological Conditions

  • Timeline Context: The lecture is conducted in February, during the second week of classes, although it feels like the first week.

  • Focus: The discussion centers on chronic neurological conditions, specifically focusing on the role of acetylcholine.

Acetylcholine Overview

  • New Neurotransmitter: Acetylcholine is introduced as a new neurotransmitter, with previous discussions focusing on monoamines (e.g., epinephrine, norepinephrine, serotonin).

  • Module Objectives: The session aims to cover chronic dysfunction related to acetylcholine and briefly touch on dopamine issues related to neurological conditions.

Key Chronic Neurological Conditions

  • Primary Conditions Discussed:

    • Myasthenia Gravis (MG)

    • Alzheimer's Disease (AD)

Comparison and Connection

  • Commonality: Both conditions involve an insufficiency of acetylcholine, albeit with different physiological mechanisms.

    • Myasthenia Gravis: Characterized by receptor problems due to an autoimmune attack, leading to reduced muscle contraction.

    • Alzheimer's Disease: Involves degeneration of cholinergic neurons and reduced production of acetylcholine.

Mechanisms of Acetylcholine

  • Synthesis and Function: Acetylcholine is synthesized in the presynaptic neuron, released into the synaptic cleft, and binds to receptors on the postsynaptic neuron.

  • Physiological Roles: Acetylcholine plays a role in:

    • Muscle contraction at the neuromuscular junction.

    • Enhancing memory, attention, and cognition within the brain.

Pathophysiology of Myasthenia Gravis

  • Receptor Problems: Myasthenia Gravis involves:

    • Autoantibodies attacking acetylcholine receptors at the neuromuscular junction.

    • Sufficient acetylcholine production but insufficient receptors leading to muscle weakness.

Pathophysiology of Alzheimer's Disease

  • Neuronal Degeneration: In Alzheimer's Disease:

    • There is chronic degradation and atrophy of presynaptic cholinergic neurons.

    • Insufficient acetylcholine production while receptors remain intact.

Pharmacology of Acetylcholine Enhancers

  • Pharmacologic Approach: The goal is to inhibit acetylcholine breakdown to increase availability.

  • Cholinesterase Inhibitors:

    • Types include neostigmine, physostigmine, and pyridostigmine.

    • Edrophonium: Short-acting, used primarily for diagnosis, not treatment.

Myasthenia Gravis Treatment

  • Primary Drug: Neostigmine is used to treat Myasthenia Gravis by increasing acetylcholine at the neuromuscular junction.

  • Dosage Considerations: Dosages must be individualized based on patient response.

  • Crisis Management:

    • Myasthenic Crisis: Insufficient cholinesterase inhibitors lead to muscle weakness, especially respiratory muscles necessitating ventilatory support.

    • Cholinergic Crisis: Excessive cholinesterase inhibitors lead to an overabundance of acetylcholine, causing excessive salivation, lacrimation, urination, diarrhea, gastrointestinal cramping, and potential respiratory distress.

  • Mnemonic for Cholinergic Effects: SLUDGE (Salivation, Lacrimation, Urination, Diarrhea, Gastrointestinal cramping, Emesis)

    • Killer B’s: Bradycardia, Bronchospasm, Bronchorrhea.

Managing Cholinergic and Myasthenic Crisis

  • Cholinergic Crisis Management: Involves stopping the cholinesterase inhibitor and administering atropine to manage bradycardia and respiratory issues.

  • Myasthenic Crisis Management: Administer more cholinesterase inhibitors to restore acetylcholine availability.

Alzheimer’s Disease Treatment

  • Primary Drugs: Donepezil, rivastigmine are used mainly for mild to moderate Alzheimer’s disease to slow down the degeneration of neurons.

  • Limitations: Current treatments do not cure Alzheimer’s disease; they only mitigate symptoms.

  • Adverse Effects: Common effects include bradycardia, gastrointestinal issues, and risk of falls due to dizziness.

Dopamine and Movement Disorders

  • Connection to Parkinson's Disease: Parkinson's disease involves insufficient dopaminergic activity leading to movement problems.

    • Distinguishing Parkinson’s Disease and Parkinsonism: True Parkinson’s disease involves neurodegeneration leading to low dopamine levels, whereas Parkinsonism refers to drug-induced conditions affecting dopamine levels.

Treatment of Parkinson's Disease

  • **Key Medications:

    • Levodopa: Converts to dopamine; often combined with carbidopa to decrease its peripheral breakdown.

    • Pramipexole and Ropinirole: Directly stimulate dopamine receptors (dopamine agonists).

    • Amantadine: Increases dopamine release and minimizes reuptake.

  • Adverse Effects Overview: Common side effects include nausea, orthostatic hypotension, unwanted movements, behavior changes, and potential hallucinations.

Additional Considerations in Treatment

  • On-off Phenomenon: Fluctuations in medication efficacy leading to periods of mobility difficulties.

  • Dietary Considerations: Protein intake can impact the effectiveness of Levodopa, specifically parenteral rich foods should be consumed cautiously throughout the day.

  • Importance of Fall Safety: Patients, especially elderly ones, are at increased risk of falling due to dizziness and cognitive impairments.

Conclusion

  • Key Summary: The focus on the roles of neurotransmitters (specifically acetylcholine and dopamine) is essential in the understanding of chronic neurological conditions and their pharmacological management. Individualized treatment and understanding the unique challenges of each disorder facilitate better patient care.